Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met

Anaplastic lymphoma kinase (ALK) is a validated molecular target for patients harboring ALK rearrangement, which triggers the development of ALK inhibitors. However, the activation of mesenchymal-epithelial transition factor (c-Met) has emerged as a common cause of acquired resistance induced by sel...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Cancer Res
Asıl Yazarlar: Wang, Lei, Gao, Mingzhao, Tong, Mengya, Xie, Chengying, He, Ye, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: e-Century Publishing Corporation 2018
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129499/
https://ncbi.nlm.nih.gov/pubmed/30210922
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller